Zydus receives final approval from the USFDA for Doxycycline for Injection USP

Ahmedabad, 30 September 2017

Zydus Cadila has received the final approval from the USFDA to market Doxycycline for Injection USP, 100 mg per vial and 200 mg per vial (Single-Dose Vial). The drug is a broad spectrum antibiotic and is indicated to treat or prevent a variety of infectious disorders that are proven or strongly suspected to be caused by susceptible bacteria. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

***